Formulation and development of colon-targeted mucopenetrating metronidazole nanoparticles by Kaur, Sukhbir et al.
Kaur et al 
Trop J Pharm Res, May 2017; 16(5): 967  
 
Tropical Journal of Pharmaceutical Research May 2017; 16 (5): 967-973 
ISSN: 1596-5996 (print); 1596-9827 (electronic) 
© Pharmacotherapy Group, Faculty of Pharmacy, University of Benin, Benin City, 300001 Nigeria.  
All rights reserved. 
 
Available online at http://www.tjpr.org 
http://dx.doi.org/10.4314/tjpr.v16i5.1 
Original Research Article 
 
 
Formulation and development of colon-targeted 
mucopenetrating metronidazole nanoparticles 
 
Sukhbir Kaur1,2, RK Narang1 and Geeta Aggarwal3 
1Department of Pharmaceutics, ISF College of Pharmacy, Moga, 2IKG Punjab Technical University, Jalandhar, 3Rayatand 
Bahra Institute of Pharmacy, Mohali, Punjab, India 
 
*For correspondence: Email: k_sukhbir@yahoo.co.in, drrknisf@gmail.com, geetaaggarwal17@gmail.com 
 
Sent for review: 24 December 2016        Revised accepted: 21 April 2017 
 
Abstract 
Purpose: To formulation and develop colon-targeted mucopenetrating metronidazole nanoparticles. 
Methods: Metronidazole-loaded chitosan nanoparticles with a pH-sensitive polymer, hydroxyl propyl 
methyl cellulose phthalate (HPMCP), were prepared by ionic gelation technique and then coated with 
Eudragit S100 by solvent evaporation method. The nanoparticles were optimized using one variable at 
a time (OVAT) approach. Further, the nanoparticles were evaluated by scanning electron microscopy 
(SEM) and zeta sizer, as well as for in-vitro release. Muco-adhesion was evaluated by modified 
bioadhesion detachment force measurement balance and muco-penetration of fluorescein 
isothiocyanate (FITC) labeled optimized nanoparticles was determined by microscopic technique 
Results: Morphological assessment results revealed smooth, spherical particles with homogeneous 
distribution and polydispersity index (PDI) of 0.213. The optimized formulation showed particle size of 
202 ± 27 nm, zeta potential of 26.9 ± 2.4 mV as well as and entrapment efficiency of 79 ± 5.4 %. There 
was significant difference in drug release between coated (8.46 ± 2.49 %) and uncoated (28.96 ± 4.04 
%) nanoparticles at the 5th h in simulated gastric conditions. Muco-adhesion data revealed that 
uncoated nanoparticles (14.98 x 103 dyne/cm2) showed higher muco-adhesion detachment force 
compared to coated (12.34 x 103 dyne/cm2) nanoparticles. Muco-penetration results confirm the 
retention (for up to 12 h) of the developed formulation at the target site for enhanced therapeutic 
exposure of the entrapped drug.    
Conclusion: Eudragit S100 coating of chitosan-HPMCP nanoparticles promotes efficient drug targeting 
and thus provides a strategy for treating mucosal infections. .  
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Amoebiasis is a chronic disorder of intestinal 
mucosa with organ vulnerability to colon, caused 
by one celled parasite Entamoeba histolytica (E. 
histolytica). Oral route is most preferred because 
of easy durg delivery in the treatment of such 
diseases. Metronidazole is a drug of choice in 
treating amoebiasis.  It gets completely absorbed 
in approximately 1 h after oral administration. 
Thus, it is ineffective in conventional delivery 
system to cure colon infection [1]. Metronidazole 
acts by disrupting the helicle structure of DNA 
and thus inhibiting nucleic acid synthesis of 
protozoa. [2]. Most of the drugs are ineffective in 
complete eradication of the E. histolytica, due to 
poor penetration of the delivery system across 
the mucus membrane. As the parasites reside 
and colonize deep into the colonic mucosa and in 
the intracellular space between the epithelial 
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cells [3]. Nanoparticles offer many advantages as 
a delivery system such as easy permeability, 
high drug loading, no toxicity, resistance to 
degradation [4], taken up readily in inflammation 
area, attach and penetrate better to the mucus 
due to its relatively small mass [5]. 
 
Chitosan offer many advantages as a delivery 
carrier. It is a cationic polysaccharide, thus 
readily attaches to the negatively charged 
surface of mucus membrane [6], low toxicity [7], 
biodegradable [8], antimicrobial, and anti-
cancerous [9]. But it undergoes easy dissolution 
at low pH in stomach [10]. This can be prevented 
by ionic gelation of chitosan with HPMCP and 
further coating with Eudragit S100, which 
dissolves only when the pH is above 7 [11]. Thus 
the objective of the study was to formulate 
Eudragit S100-coated pH-sensitive nanoparticles 
of metronidazole. The nanoparticles were then 
evaluated for morphology, particle size, zeta 
potential, PDI, drug loading, in-vitro release, 






Metronidazole and HPMCP HP55 grade were 
gifts from La Pharmaceuticals, Ludhiana, Punjab, 
India. Chitosan (viscosity grade 200-400 mPas), 
Eudragit S100 and FITC were purchased from 
Sigma Aldrich, USA.  Trehalose dihydrate and 
dialysis membrane (MW, 10 - 12 K Da) from Hi 
Media Labs, Pvt Ltd, Mumbai, India. The other 
materials used were of analytical grade. 
 
Formulation of CS-HPMCP nanoparticles 
 
The nanoparticles were formulated by 
polyelectrolyte complexation of positively 
charged chitosan and negatively charged enteric 
coating polymer HPMCP using modified ionic 
gelation method with magnetic stirring at room 
temperature [12]. In brief, different 
concentrations of chitosan (0.1 - 0.2 % w/v) was 
prepared in acetic acid (1 % v/v) at pH 5. 
HPMCP (0.1 - 0.2 % w/v) solution was prepared 
in sodium hydroxide (0.1 M).  This solution was 
added slowly to chitosan solution containing 
metronidazole (0.05 - 0.1 % w/v) under magnetic 
stirring for 30 min at 100 rpm. The pH of final 
dispersion was kept at 5.5. The dispersion was 
then centrifuged for 30 min at a speed of 20,000 
rpm (42,000 g) at 4 ºC. Supernatant was used to 
measure free metronidazole. Collected 
nanoparticles were washed using double-distilled 
water, freeze at – 20 ºC in deep freezer, freeze 
dried in a lyophilizer (Martin Christ model Alpha 
1-2 LD plus) using using D (+) 0.5 % w/v of 
trehalose dihydrate as a cryoprotectant at – 55 
ºC at a pressure of 0.01 mm of Hg.  
 
Coating of nanoparticles 
 
The solvent evaporation method using rotary 
evaporator (Super Fit, Ambala, India) was 
applied to coat metronidazole nanoparticles with 
Eudragit S100 [13]. Acetone solution 12 % w/v 
was used to prepare coating solution. 
Nanoparticles (100 mg) were dispersed in 1:10 
core: coat coating solution. The procedure was 
carried until sufficient coating was attained. The 
coated nanoparticles were then dried and 
weighed. 
 




SEM (ZEISS EVO Series Scanning Electron 
m icroscope Model EVO50, Jeol, Japan) was 
used to determine morphology of nanoparticles. 
Sample was mounted on the sample holder and 
gold coating was done for microscopy. 
 
Particle size PDI and zeta potential  
 
Zeta sizer (Beckman Coulter, Delsa nano C) was 
used to determine particle size distribution, zeta 
potential and PDI. Samples were dispersed in 
double distilled water and were sonicated prior to 
estimation. All measurements were performed in 
triplicate (n = 3).  
 
Drug entrapment   
 
Nanoparticles obtained were digested for 20 min 
in acetic acid (2 %) solution using probe 
sonicator (Misonix, U.S.A.) and then centrifuged 
for 5 min at 1000 rpm.  Metronidazole 
concentration was estimated in supernatant 
using UV Spectrophotometer (UV-1700-
Pharmaspec Shimadzu, Japan). Drug 
entrapment (E) of formulations was calculated 
using Eq 1. 
 
E (%) = {(Xt - Xs)/Xt)100.……………….(1) 
 
where Xt = total amount of drug added and Xs = 
amount of drug in the supernatant. 
 
In-vitro release study  
 
In-vitro release was carried out using dialysis 
membrane (Hi Media, Mumbai, India) in Franz 
Diffusion cell which was thermostatically 
maintained at 37 °C ± 1 °C in simulated gastric 
and colonic fluid. The donor compartment 
containing 2 ml suspension (equivalent to 10 mg) 
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of metronidazole, re-suspensed by mixing for 5 
sec, in Tween 80 (1 % w/v) solution in simulated 
gastric/colonic fluid [14]. Samples of I ml each 
was taken from receptor compartment at different 
time intervals and replace with fresh media in 
equal volume. Samples were diluted where 
necessary, filtered and analyzed spectro-
photometrically at 277 nm. 
 
FITC-conjugated chitosan polymer synthesis 
 
FITC conjugated chitosan was synthesized using 
a previously reported method [15]. Chitosan was 
dissolved in 20 ml of acetic acid (0.1 M). It was 
kept overnight under stirring. Then under 
constant stirring methanol (20 ml) and 10 ml of 
FITC solution (2mg/ml in methanol) was added to 
chitosan solution. The reaction mixture was kept 
for 3 h in dark room.  
 
Then sodium hydroxide (0.5 M) was added to the 
reaction mixture till a pH of 8 - 9 to precipitate 
FITC labeled chitosan. After that it was 
centrifuged for 10 min at 20,000 rpm.  The 
precipitate then washed thoroughly with 
deionised distilled water till washing medium was 
completely free from FITC fluorescence. The 
FITC conjugated chitosan was then freeze dried. 
 
Preparation of FITC-labeled CS-HPMCP 
nanoparticles 
 
FITC labeled chitosan nanoparticles were 
prepared using HPMCP solution as cross-linking 
agent by a reported ionic gelation method [12]. 
Briefly aqueous solution of HPMCP (0.2 % w/v) 
(pH 5.0) in sodium hydroxide (0.1 M), was added 
with the help of 1 ml syringe into 0.2 % w/v FITC 
labeled chitosan solution (pH 5) prepared in 1 % 
v/v acetic acid The nanoparticles were collected 
by centrifugation for 30 min at 25,000 rpm 
(42,000 g), washed and freeze dried. 
 
Bio-adhesion detachment force study  
 
The bio-adhesive performance of 10 mg Eudragit 
S100 coated and uncoated nanoparticles was 
calculated by measuring the force needed to 
detach the nanoparticles from the pig gastric 
mucosal tissue using modified [16] bio-adhesion 
detachment force measurement balance.  The 
bio-adhesion detachment force (BF) in 
dynes/cm2 was calculated using equation (2): 
 
BF = (m.g)/A .…………………..(2) 
 
where m = weight (in grams) added to the 
balance to detach the membrane, g = 
acceleration due to gravity (m/s2) and A = 
exposed area of the tissue. 
In-vivo mucopenetration study 
 
The animal protocols of the present study was 
carried out in accordance to the guiding 
principles of laboratory animal care (NIH 
Publication No. 85-93, revised 1985) [17] and 
were approved by Committee for the Purpose of 
Control And Supervision of Experiments on 
Animals (CPCSEA) (ref no. IAEC/M17/311/2016) 
of ISF College of Pharmacy, Moga, Punjab, 
India. FITC labeled CS-HPMCP (10 mg/2 ml) 
nanoparticles were administered using oral 
feeding canula to Wistar rats (n=12).  After 
interval of 5, 8 and 12 h, three animals each time 
were sacrificed and colon portion from each 
animal was excised, washed with normal saline 
and antrum region was fixed () in formalin (10 
%), sectioned (10µm)  and stained with eosin 
[18]. Then it was seen under digital microscope 
(100X) (Motic DMWB series) using Motic Images 
plus 2.0 software and inverted fluorescent 
microscope (40X) (Olympus) to analyze the 
localization, mucoadhesion and mucopenetration 
of fluorescent nanoparticles. 
 
Accelerated stability studies  
 
A stability study was carried out on the optimized 
batch (CHP5) to assess the stability of 
nanoparticles by placing in stability chamber, 
adjusted at different temperature, i.e., 40 ± 0.5, 
50 ± 0.5 and 60 ± 0.5º C, at a relative humidity of 
75 ± 5 %, as well as at 25º C and relative 
humidity of 57.6 ± 0.4 % for a period of 12 
weeks. The nanoparticles were thereafter 





The data are presented as mean ± standard 
deviation (SD). Where appropriate, differences 
between groups were evaluated using Student’s 
t-test (two groups) at an alpha level of 0.05 using 





Preparation and optimization of nanoparticles 
 
The nanoparticles were prepared by ionic 
gelation technique. Prepared nanoparticles were 
then coated by solvent evaporation method. The 
various formulation parameters such as polymer 
concentration and amount of drug were 
optimized. The resultant nanoparticles were then 
characterized for particle size, PDI, zeta potential 
and entrapment efficiency. The result 
demonstrated that the concentration of polymer 
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constituents play a key role in determining the 
morphology of prepared nanoparticles. The 
results were presented in Table 1. 
 
On the basis of experimental finding, CHP5 
formulation of nanoparticles was selected as 
optimized formulation on the basis of particle size 
(202 ± 27 nm), zeta potential (26.9 ± 2 mV), PDI 
(0.213) and entrapment efficiency (79.8 ± 5.4 %). 
Further results indicate that drug polymer ratio at 
1:1 produced nanoparticles with desired size 
range and entrapment efficiency. Therefore 
formulation CHP5 was finely selected and 
considered for further study. The selected 
formulation was subjected for coating with 
Eudragit S100 by solvent evaporation. The 
coating efficiency was adjudged by in-vitro 




The SEM of freeze dried optimized coated and 
uncoated nanoparticles at 200x magnification 
showed smooth, spherical porous particles 
(Figure not shown). At the concentration of 
chitosan 0.1 % w/v the particles size was 
diverging between 202 - 236 nm and at 0.2 % 
w/v concentration 272 – 344 nm which is shown 




The zeta potential is mainly affected by chitosan 
concentration and varied from 26.9 - 49.7 mV 
when chitosan concentration ranges from 0.1 - 
0.2 % w/v. It may be said that availability of 
protonated amino groups are higher with 
increasing concentration of chitosan, and for 
optimized formulation Zeta potential was found to 




The minimum size i.e. 202 nm (Table 1) was 
observed with minimum concentration of 
chitosan and HPMCP and the maximum size, 
i.e., 344 nm was observed with maximum 
concentration of the polymers. Optimized 
formulation has particle size of 202.7 ± 27 nm. 
 
Drug entrapment (PDE) 
 
The PDE of the nanoparticles ranged from 28.5 - 
86.7 % and was highest at the highest 
concentrations of chitosan and HPMCP. Drug 





In vitro release performed on coated and 
uncoated CS-HPMCP nanoparticles to estimate 
drug release at colonic pH. In the current study, 
release determined in simulated gastric (0.1 M 
HCl solution) and colonic fluid (pH 6.8). 
Metronidazole released from the coated 
nanoparticles after 2 h in 0.1 M HCl was 5.57 ± 
1.34 % whereas in uncoated nanoparticles, it 
was 16.08 ± 3.51 %. 
 
Figure 1: Release profile of optimized Eudragit S100-
coated (∆ EU-CS-HPMCP) and uncoated (◊ CS-
HPMCP) nanoparticles 
 
Bioadhesion detachment force  
 
The bioadhesion detachment force studies on 
optimized nanoparticles (n=3) showed 
detachment force up to 12.34 * 103 dyne / cm2 for 
coated and for the uncoated it was up to 14.98 * 
103 dyne / cm2. 
 
Table 1: Physicochemical properties of nanoparticles 
 
Formulation 













CHP1 0.1 0.1 0.05 225±17 32.5±2.3 28.5±4.4 0.219 
CHP2 0.2 0.1 0.05 274±23 40.4±4.7 66.5±5.6 0.316 
CHP3 0.1 0.2 0.05 236±34 37.6±3.9 34.4±4.2 0.242 
CHP4 0.2 0.2 0.05 294±21 47.7±4.2 59.6±4.9 0.268 
CHP5 0.1 0.1 0.1 202±27 26.9±2.4 79.8±5.4 0.213 
CHP6 0.2 0.1 0.1 272±32 43.6±3.3 75.8±3.3 0.133 
CHP7 0.1 0.2 0.1 228±18 49.7±4.3 53.5±3.8 0.322 
CHP8 0.2 0.2 0.1 344±37 48.3±3.8 86.7±5.3 0.298 
Kaur et al 
Trop J Pharm Res, May 2017; 16(5): 971  
 
 
   Figure 2: Nanoparticles to the colonic mucosa at 5th, 8th and 12th h, respectively 
 
In-vivo mucopenetration  
 
The in-vivo mucopenetration studies of FITC 
labeled Eudragit S100 coated nanoparticles in 
Wistar rats revealed localisation and 
internalisation (Figure 2) of good number of 
nanoparticles up to 12 h. The histopathology 
photographs of nanoparticles revealed that in the 
first five hours the nanoparticles got adhered to 
the mucosa, and after that the penetration took 
place [19]. After time period of 8 h and till 12 h, 
the nanoparticles were seen in the mucus layer 
and were penetrated deep into mucosa near 
epithelial cell layer as observed by high 
fluorescence intensity near the gastric 
epithelium.The observed muco-penetration is 
attributed to decline in mucoadhesion because of 
reduced surface positivity of nanoparticles, which 
resulted in increased motility in colonic mucosa 
[20,21]. 
 
Stability of nanoparticles 
 
The optimized formulation (CHP5) of 
nanoparticles was subjected to various 
temperature and humidity conditions for 12 
weeks exhibited no change in colour and 
apperance. The chemical stability results have 
shown that the percent drug remaining was 
found to be 99.35 %, 96.45 %, 92.34 % and 
86.57 % at 25 ºC, 40 ºC, 50 ºC and 60 ºC 
respectively. There was statistically insignificant 
difference in bio-adhesion strength of 
nanoparticles during 12 weeks at 25 ºC and 40 
ºC. The regression analysis of stability data 
indicates that the drug degradation follows first 




Various researchers have prepared chitosan 
nanoparticles using tripolyphosphate, sodium 
sulphate, poly-γ-glutamic acid, dextran sulphate, 
 
Figure 3: Accelerated Stability Studies of optimized 
formulation (CHP5) at temperature 25º C (◊), 40º C 
(□), 50º C (∆) and 60º C (×) 
 
anionic cyclodextrin [22], Eudragit S100, Eudragit 
L100 [23] as polyanion. However most of 
chitosan based nanoparticles have inadequate 
stability due to its dissociation at low pH.  This is 
because of free amine group protonation of 
chitosan. This nanoparticles does not reach to 
small intestine and colon.  
 
Therefore in order to stabilize chitosan 
nanoparticles HPMCP was used as anionic 
polymer. Further, the ratio between chitosan and 
HPMCP is critical to control the particle size and 
PDI. Additionally, the pH was considered as an 
important factor since it determines cross-linking 
degree and also the pH of the delivery site [24].  
 
Zeta potential >25 mV can indicate 
nanoparticle’s stability. In our study zeta potential 
remained above + 25 mV at the selected pH, 
thus confirming that the system remains stable 
and there was no aggregation. In addition to its 
net positive potential help in initial adhesion of 
nanoparticles to the surface of gastric mucosa.  
Amino groups of chitosan interact with mucin 
glycoproteins, sialic acid and other anionic 
moieties present on gastric mucosa [25,26]. 
Coated nanoparticles have comparatively less 
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mucoadhesive detachment force, which may be 
due to decrease in surface amino groups [19] 
.This reduced bioadhesion can facilitate in 
infiltration of  nanoparticles to gastric mucosa 
enhanced penetration and accumulation at the 




The results of the present study suggest that 
entrapment of metronidazole in Eudragit S100 
chitosan-HPMCP nanoparticles releases 
maximum content of the drug at colon in vitro. 
Furthermore, due to their very small size, the 
nanoparticles are capable of infiltrating mucus 
lining and could thus aid in the eradication of the 







The authors are grateful to Chairman and Deptt 
of Pharmaceutics, ISF College of Pharmacy, 
Moga, Punjab, India for providing necessary 
facilities to complete the research work. 
 
Conflict of Interest 
 
No conflict of interest associated with this work. 
 
Contribution of Authors 
 
The authors declare that this work was done by 
the authors named in this article and all liabilities 
pertaining to claims relating to the content of this 
article will be borne by them.  
 
Open Access  
 
This is an Open Access article that uses a fund-
ing model which does not charge readers or their 
institutions for access and distributed under the 
terms of the Creative Commons Attribution 
License (http://creativecommons.org/licenses/by/ 
4.0) and the Budapest Open Access Initiative 
(http://www.budapestopenaccessinitiative.org/rea
d), which permit unrestricted use, distribution, 
and reproduction in any medium, provided the 




1. Krishnaiah YSR, Reddy PBR, Satyanarayanan V, 
Karthikeyan RS. Studies on development of oral colon 
targeted drug delivery system for metronidazole in 
treatment of amoebiasis. Int J Pharm 2002; 236: 43-55. 
2. Mohire NC, Yadav AV. Novel approach to formulate β-
cyclodextrin complexed mouth dissolving tablet of 
metronidazole and its in vitro evaluation. J Pharm Res 
2010; 03: 662-667. 
3. Ozbek O, Odev K, Solak Y, Fevzioglu B. An exceedingly 
rare type of renal cyst: amoebic cyst. Quart J Med 2013; 
106: 281-282.  
4. Laroui H, Viennois E, Bo X, Brandon S, Geem D, Timothy 
L, Merlin D. Fab’-bearing siRNA TNFα-loaded 
nanoparticles targeted to colonic macrophages offer an 
effective therapy for experimental colitis. J Control 
Release 2014; 28: 41-53.  
5. Lamprecht A, Schäfer U, Lehr C-M. Size-dependent 
bioadhesion of micro and nanoparticulate carriers to the 
inflamed colonic mucosa. Pharm Res 2001; 18: 788-
793. 
6. Plapied L, Vandermeulen G, Vroman B, Préat V, Rieux 
D. Bioadhesive nanoparticles of fungal chitosan for oral 
DNA delivery. Int J Pharma 2010; 398: 210-218. 
7. Gao JQ, Zhao QQ, Shua WP, Zhou J, Tang GP, Ping G, 
Liang WQ, Quan W, Tabata Y, Hu YL. Gene-carried 
chitosan-linked-PEI induced high gene transfection 
efficiency with low toxicity and significant tumor-
suppressive activity. Pharmaceut Nanotechnol 2010; 
387: 286-294. 
8. Bagheri KS, Taghizadeh SM, Mirzade H. An investigation 
on the short-term biodegradability of chitosan with 
various molecular weights and degrees of deacetylation. 
Carbohydr Polym 2009; 78: 773778. 
9. Gan Q, Wang T, Cochrane C, McCarron P. Modulation of 
surface charge, particle size and morphological 
properties of chitosan–TPP nanoparticles intended for 
gene delivery. Colloids Surf B 2005; 44: 6573. 
10. George M and Abraham TE. Polyionic hydrocolloids for 
the intestinal delivery of protein drugs: alginate and 
chitosan – A review. J Control Release 2006; 114: 114. 
11. Makhlof A, Tozuka Y, Takeuchi H. pH-Sensitive 
nanospheres for colon-specific drug delivery in 
experimentally induced colitis rat model. Eur J Pharm 
Biopharm 2009; 72: 1-8. 
12. Makhlof A, Tozukaa Y, Takeuchia H. Design and 
evaluation of novel pH-sensitive chitosan nanoparticles 
for oral insulin delivery. Eur J Pharm Sci 2011; 42: 
445451. 
13. Maestrelli F, Zerrouk N, Cirri M, Mennini N, Mura P.  
Microspheres for colonic delivery of ketoprofen-
hydroxypropyl-beta-cyclodextrin complex. Eur J Pharm 
Sci 2008; 10: 1-11.  
14. Meltem C, Alptug A, Yucel K. Formulation and In vitro 
Characterization of Eudragit® L100 and Eudragit®L100-
PLGA nanoparticles containing diclofenac sodium. 
AAPS PharmSciTech 2010; 11: 1250-1256. 
15. Qaqish RB and Amiji MM. Synthesis of a fluorescent 
chitosan derivative and its application for the study of 
chitosan-mucin interactions. Carbohydr Polym 1999; 38: 
99107. 
16. Kerec M, Bogataj M, Mugerle B, Ga perlin M, Mrhar A. 
Mucoadhesion on pig vesical mucosa: influence of 
Kaur et al 
Trop J Pharm Res, May 2017; 16(5): 973  
 
polycarbophil/calcium interactions. Int J Pharmaceutics 
2002; 241: 135143. 
17. Guide for the Care and Use of Laboratory Animals. NIH 
Publication No. 85-23. Revised 1985. 
18. Ramteke S, Ganesh N, Bhattacharya S, Jain NK. 
Amoxicillin, clarithromycin and omeprazole based 
targeted nanoparticles for the treatment of H. pylori. J 
Drug Target 2009; 17: 225-234. 
19. Lai SK, Wang YY, Hanes J. Mucus-penetrating 
nanoparticles for drug and gene delivery to mucosal 
tissues. Adv Drug Deliv Rev 2009; 61: 158-171. 
20. Suk JS, Lai SK, Wang YY, Ensign LM, Zeitlin PL, Boyle 
MP, Hanes J. The penetration of fresh undiluted sputum 
expectorated by cystic fibrosis patients by non-adhesive 
polymer nanoparticles. Biomat 2009; 30: 2591-2597. 
21. Tang BC, Dawson M, Lai SK, Wang YY, Suk JS, Yang M, 
Zeitlin P, Boyle MP, Fu J, Hanes J. Biodegradable 
polymer nanoparticles that rapidly penetrate the human 
mucus barrier. Proc Nat Acad Sci USA 2009; 106: 
19268-19273. 
22. Amidi M, Mastrobattista E, Jiskoot W, Hennink WE. 
Chitosan-based delivery systems for protein 
therapeutics and antigens. Adv Drug Deliv Rev 2010; 
62: 5982. 
23. Kibbe AH. Handbook of pharmaceutical excipients, 3rd 
edn, American Pharmaceutical Association, Washington 
DC, 2000; pp 401-406. 
24. Gupta KC and Jabrail FH. Effects of degree of 
deacetylation and crosslinking on physical 
characteristics, swelling and release behavior of 
chitosan microspheres. Carbohydr Polym 2006; 66: 43-
54. 
25. Arora S, Gupta S, Narang RK, Budhiraja RD. Amoxycillin 
loaded chitosan-alginate polyelectrolyte complex 
nanoparticles as mucopenetrating delivery system for H. 
pylori. Sci Pharm 2011; 79: 673–694.  
26. Deacon MP, Mc GS, Roberts CJ, Williams PM, Tendler 
SJ, Davies MC, Davis SS, Harding SE. Atomic force 
microscopy of gastric mucin and chitosan mucoadhesive 
systems. Biochem J 2000; 348: 557563. 
 
